These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 36951394

  • 1. The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease.
    Hammond HH, Ames MK, Domenig O, Scansen BA, Yang NT, Wilson MD, Sunshine E, Brunk K, Masters A.
    J Vet Intern Med; 2023; 37(3):875-886. PubMed ID: 36951394
    [Abstract] [Full Text] [Related]

  • 2. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK, Atkins CE, Eriksson A, Hess AM.
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [Abstract] [Full Text] [Related]

  • 3. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
    Galizzi A, Bagardi M, Stranieri A, Zanaboni AM, Malchiodi D, Borromeo V, Brambilla PG, Locatelli C.
    BMC Vet Res; 2021 Jan 07; 17(1):15. PubMed ID: 33413406
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z, Nooshirvani P, Shirani D, Masoudifard M.
    BMC Vet Res; 2022 Dec 23; 18(1):448. PubMed ID: 36564735
    [Abstract] [Full Text] [Related]

  • 5. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Newhard DK, Jung S, Winter RL, Duran SH.
    J Vet Intern Med; 2018 Sep 23; 32(5):1555-1563. PubMed ID: 30084228
    [Abstract] [Full Text] [Related]

  • 6. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N, Nemec Svete A, Ihan A, Pohar K, Domanjko Petrič A.
    J Vet Intern Med; 2021 Sep 23; 35(5):2112-2122. PubMed ID: 34236111
    [Abstract] [Full Text] [Related]

  • 7. Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease.
    Christiansen LB, Cremer SE, Helander A, Madsen T, Reimann MJ, Møller JE, Höglund K, Ljungvall I, Häggström J, Olsen LH.
    Vet J; 2019 Aug 23; 250():36-43. PubMed ID: 31383418
    [Abstract] [Full Text] [Related]

  • 8. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H, Takiguchi M.
    J Vet Intern Med; 2017 Mar 23; 31(2):316-325. PubMed ID: 28145607
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R, Sabetti MC, Crosara S, Quintavalla C, Romito G, Mazzoldi C, Fidanzio F, Cescatti M, Bertazzolo W, Giunti M, Dondi F.
    J Vet Intern Med; 2022 Nov 23; 36(6):2053-2062. PubMed ID: 36196592
    [Abstract] [Full Text] [Related]

  • 10. Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease.
    Li Q, Freeman LM, Rush JE, Laflamme DP.
    Int J Mol Sci; 2015 Jun 19; 16(6):14098-108. PubMed ID: 26101868
    [Abstract] [Full Text] [Related]

  • 11. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ, Ljungvall I, Hillström A, Møller JE, Hagman R, Falk T, Höglund K, Häggström J, Olsen LH.
    Vet J; 2016 Mar 19; 209():113-8. PubMed ID: 26831162
    [Abstract] [Full Text] [Related]

  • 12. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q, Wu Z, Li L, Zhou H, Chen Y, Guo S, Guo Y, Ma X, Zhang J, Feng W, Cui X, Qiu C, Xu M, Deng G.
    J Proteomics; 2023 Jun 30; 282():104924. PubMed ID: 37146676
    [Abstract] [Full Text] [Related]

  • 13. Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
    Adin D, Kurtz K, Atkins C, Papich MG, Vaden S.
    J Vet Intern Med; 2020 Jan 30; 34(1):53-64. PubMed ID: 31769114
    [Abstract] [Full Text] [Related]

  • 14. Changes in renin-angiotensin-aldosterone system during cardiac remodeling after mitral valvuloplasty in dogs.
    Cheng CJ, Mandour AS, Yoshida T, Watari T, Tanaka R, Matsuura K.
    J Vet Intern Med; 2022 Mar 30; 36(2):397-405. PubMed ID: 34994485
    [Abstract] [Full Text] [Related]

  • 15. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
    Lee CM, Jeong DM, Kang MH, Kim SG, Han JI, Park HM.
    Am J Vet Res; 2017 Apr 30; 78(4):440-446. PubMed ID: 28345991
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.
    Vereb M, Atkins CE, Adin D, Blondel T, Coffman M, Lee S, Guillot E, Ward JL.
    J Vet Intern Med; 2024 Apr 30; 38(1):51-60. PubMed ID: 37909399
    [Abstract] [Full Text] [Related]

  • 17. Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease.
    Larouche-Lebel É, Loughran KA, Oyama MA, Solter PF, Laughlin DS, Sánchez MD, Assenmacher CA, Fox PR, Fries RC.
    J Vet Intern Med; 2019 Jul 30; 33(4):1571-1584. PubMed ID: 31254308
    [Abstract] [Full Text] [Related]

  • 18. Biopterin status in dogs with myxomatous mitral valve disease is associated with disease severity and cardiovascular risk factors.
    Reimann MJ, Häggström J, Mortensen A, Lykkesfeldt J, Møller JE, Falk T, Olsen LH.
    J Vet Intern Med; 2014 Jul 30; 28(5):1520-6. PubMed ID: 25274442
    [Abstract] [Full Text] [Related]

  • 19. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A, Borgarelli M, Abbott JA, Menciotti G, Crosara S, Häggström J, Lahmers S, Rosenthal S, Tyrrell W.
    J Vet Cardiol; 2022 Jun 30; 41():99-120. PubMed ID: 35316716
    [Abstract] [Full Text] [Related]

  • 20. Pulmonary-vein-to-pulmonary-artery ratio can be utilized to evaluate myxomatous mitral valve disease progression in dogs.
    Kim MS, Kim J, Seo MW, Park C.
    Am J Vet Res; 2024 Jul 01; 85(7):. PubMed ID: 38663446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.